POETYK PSO-1 (deucravacitinib vs. apremilast)
Trial question
What is the effect of deucravacitinib versus apremilast in patients with moderate-to-severe plaque psoriasis?
Study design
Multi-center
Double blinded
RCT
Population
Characteristics of study participants
32.0% female
68.0% male
N = 500
500 patients (160 female, 340 male).
Inclusion criteria: adult patients with moderate-to-severe plaque psoriasis.
Key exclusion criteria: other forms of psoriasis; history of recent infection; prior exposure to deucravacitinib or apremilast.
Interventions
N=332 deucravacitinib (at a dose of 6 mg daily).
N=168 apremilast (at a dose of 30 mg BID).
Primary outcome
≥ 75% reduction in Psoriasis Area and Severity Index at week 16
58.4%
35.1%
58.4 %
43.8 %
29.2 %
14.6 %
0.0 %
Deucravacitinib
Apremilast
Significant
increase ▲
NNT = 4
Significant increase in ≥ 75% reduction in Psoriasis Area and Severity Index at week 16 (58.4% vs. 35.1%; AD 23%, 95% CI 14.1 to 31.8).
Secondary outcomes
Significant increase in static Physician's Global Assessment score of 0 or 1 at week 16 (53.6% vs. 32.1%; AD 21.4%, 95% CI 12.7 to 30.1).
Significant increase in ≥ 90% reduction in Psoriasis Area and Severity Index at week 16 (35.5% vs. 19.6%; AD 15.8%, 95% CI 8.2 to 23.5).
Significant increase in Dermatology Life Quality Index of 0 or 1 at week 16 (41% vs. 28.6%; AD 12.3%, 95% CI 3.4 to 21.1).
Safety outcomes
No significant difference in adverse events.
Conclusion
In adult patients with moderate-to-severe plaque psoriasis, deucravacitinib was superior to apremilast with respect to ≥ 75% reduction in Psoriasis Area and Severity Index at week 16.
Reference
April W Armstrong, Melinda Gooderham, Richard B Warren et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39.
Open reference URL